Personalis NeXT Platform: A Comprehensive Platform for Tissue and Plasma Profiling to Enable Personalized Medicine

Time: 11:00 am
day: Day One


  • ImmunoID NeXT enables tumor tissue-based immunogenomics profiling, accurate assessment of mutational landscape and putative neoantigens from analytically-validated exome and transcriptome assays, state-of-the-art neoantigen presentation and binding predictions built upon high quality immunopeptidomics training data, and multiple other emerging biomarkers, all from a single sample
  • In parallel, NeXT Personal is an ultrasensitive tumor-informed plasma-based assay, designed to detect molecular residual disease and cancer recurrence at earlier timepoints, with simultaneous longitudinal variant tracking for additional insight into disease progression